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Aim of the work: To study effect of weight reduction on pulmonary function tests of obese
COPD and bronchial asthma patients.
Subjects and methods: 2 groups were included, group(G)I, 30 obese COPD and GII 30 obese
bronchial asthma patients. Pulmonary function tests were done to all participants before and after
weight reduction.
Results: GI showed increased FRC, ERV and RV signiﬁcantly, IC was signiﬁcantly decreased
and GII showed increased FEV1, FVC, FEV1/FVC, PEFR, FEF25–75% and ERV signiﬁcantly after
weight reduction.
Conclusion: Weight reduction improved airway obstruction, increased ERV, RV, FRC and
DLCO either signiﬁcant or insigniﬁcant in asthma and COPD.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Obesity has recently been identiﬁed as a major risk factor for
the development of asthma. Asthma tends to be more severe
in obese individuals, and it does not respond adequately to
treatment. As a result, the combination of obesity and asthma
is becoming a major public health issue in many countries [1].
Chronic inﬂammation is thought to initiate and perpetuate
cycles of tissue injury and repair in asthma. The persistence
of inﬂammatory cells within the airways and the up-
regulation of a number of inﬂammatory cytokines and growthfactors such as tumor necrosis factor (TNF), tumor growth
factor beta (TGF-b) and several members of the interleukin
family, as well as adhesion molecules, participate in the onset
of lung remodeling [2,3]. Yeh and Huang showed that, in the
murine model, increase in dietary cholesterol resulted in
enhanced pulmonary allergic inﬂammation [4]. It was tradi-
tionally thought that COPD patients were less likely to be
obese. The rationale was that systemic inﬂammation, in the
more advanced stages of disease, would lead to cachexia [5]
rather than overweight. However, in the most recent studies,
looking at the association of high BMI and COPD, approxi-
mately two thirds are overweight or obese [6]. A BMI below
21 kg/m2 was shown to be a negative prognosis marker [7]
while obesity appears to convey a survival advantage in
COPD, as it is the case in other chronic disease [8].rculosis.
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whereby obesity seems beneﬁcial on survival, are often biased.
Clinical experience indicates that the combined restric-
tive/obstructive deﬁcits evident in obese patients with COPD
culminate in worsening symptomatology and activity limita-
tion [9].Aim of the work
The aim of the work is to study the effect of weight reduction
on pulmonary function tests of obese COPD and bronchial
asthma patients.Subjects and methods
This study was conducted on 60 patients, in Chest
Department – Tanta university hospitals from January 2014
to April 2015, and divided into 2 groups, group(G)I, included
30 obese non-smoker COPD patients, their mean age was
47.2 ± 1.3 years (17 males and 13 females) GII included 30
obese, non-smoker bronchial asthma patients, their mean
age was 45.6 ± 2.6 years (15 males and 15 females). All
persons were subjected to the following:
(1) Full history taking and clinical examination including
body mass index (BMI).
(2) Plain X-ray chest P.A view.
(3) ECG and Echocardiography.
(4) Complete pulmonary function tests including spiromet-
ric study, lung volumes and diffusion. These were
carried out by Care Fusion Germany 234 Gmbh,
Version 03.00, V-781267-057, For JLAB software
P5.70, Disposable and accessories (Leibniz strasse
7-97204, Hoechberg, Germany, email: MarketingInfo.
EU@carefusion.com).
Spirometric study: including
Slow spirometry
The patient is asked to close his nose with the nose-clip and
approach the mouthpiece. He should breathe quite normally.
Tidal breathing was displayed on the screen. After about 8
breaths, the following was done:
(1) From normal breathing, the patient should slowly
breathe out to a maximum, slowly breathe into a
maximum and then slowly breathe out to a maximum.
(2) Then he should continue to breathe quite normally.
Forced spirometry
(1) From normal breathing, the patient should slowly
breathe out to a maximum, slowly breathe into a
maximum, breathe out as deeply and much as possible
and then breathe in as deeply and completely as
possible.(2) Then he should continue to breathe quite normally.
From this spirometric study, the following were mea-
sured: FEV1, FVC, FEV1/FVC, PEFR, FEF25–75%,
expiratory reserve volume (ERV) and estimated inspira-
tory capacity (IC).Functional residual capacity(FRC)-helium(He) rebreathing
A disinfected mouthpiece was attached to the disinfected pneu-
motach, O2 gas cylinder was opened and rebreathing bag (RB)
was connected. With starting the measurement program, the
rebreathing bag was emptied, ﬂushed with O2 and a zero
adjustment of the He gas analyzer was performed. Then the
RB bag was ﬁlled with helium and oxygen according to the
preset ﬁlling volume and its contents were analyzed. The
patient was asked to approach the mouthpiece and close his
nose with the noseclip. He should breathe quite normally.
From normal breathing, the patient was asked to slowly
breathe out as deeply as possible and then continue to breathe
normally. The patient breathed the gas mixture consisting of
about 9% helium and 32% oxygen contained in the RB bag.
In order to keep the oxygen content in the RB constant, about
250–300 ml oxygen per minute was added. The inhaled He gas
mixture was spread out evenly into the lung. The trend of the
He wash-in curve should be observed and the He value was
displayed in the status line. The following were measured: total
lung capacity (TLC), residual volume (RV) and FRC.
Diffusion-single breath (SB) study
SB gas cylinder was opened and after an automatic zero
adjustment, the actual measurement was started. The patient
should be asked to approach the mouthpiece and to close his
nose with the nose-clip. He should breathe quite normally.
After at least three breaths, the patient was asked to exhale
as deeply as possible from normal breathing. After maximal
expiration the patient was requested to inhale fast as deeply
as possible, then the patient inhaled the gas. The occlusion
time automatically started after 1/3 of inspiration. At the
end of inspiration, the patient was prevented from expiration
for the period of time set as occlusion time. The patient had
to keep the mouthpiece in his mouth and hold his breath for
10 s. The pressure curve displayed during the occlusion showed
whether the patient had held his breath or whether he had tried
to expire or inspire despite the occlusion. After the set occlu-
sion time had expired, the shutter was opened and the patient
was required to exhale smoothly, without hesitation or inter-
ruption and sampling volume was exhaled via the sampling
tube. The gas sample collected for analysis remains in the tube.
The remaining air was exhaled via the opened shutter. The
sampling valve was closed and the patient could leave the
mouthpiece and thus diffusing Capacity of carbon monoxide
(DLCOSB) was measured. Informed consent was taken from
all participants. All patients shared in weight reduction pro-
gram achieved by using low caloric diet (500–1000 calories less
than recommended daily allowance, which calculated accord-
ing to The Harris–Benedict equations) for 6 months [10]. 14
(9 from group I and 5 from group II) patients could not con-
tinue the weight reduction program and were excluded from
the study, then after weight reduction, pulmonary function
tests were repeated to all participants.
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(a) Obesity must be P30 kg/m2.
(b) Diagnosis of asthma was considered if [11]:Tabl
FEV
FVC
FEV
PEF
FEF
DLC
TLC
FRC
RV
ERV
IC
BMI
* Sig
Tabl
FEV
FVC
FEV
PEF
FEF
DLC
TLC
FRC
RV
ERV
IC
BMI
* Sig– There were symptoms of dyspnea, cough and/or
wheezing, especially nocturnal with acute episodes
which were characterized by hyperinﬂation of the
thorax, decreased breath sounds and high pitched
wheezing.
– Symptoms were worse in the presence of exercise,
viral infections, inhaled allergens, irritants, changes
in weather, strong emotional expression, stress,
menstrual cycles.
– Reversible airﬂow obstruction: increase in FEV1
>12% of predicted after inhalation of
bronchodilator.
– Alternative diagnoses were excluded.c-COPD could be diagnosed if [12]: there were chronic chest
symptoms especially cough, shortness of breath and sputum
production. FEV1/FVC ratio was <70% and percent of recov-
ery after single dose of bronchodilator was <15%.
All patients shouldn’t have cardiac troubles, DM or other
chest diseases rather than asthma and COPD.e 1 Spirometric, lung volumes and diffusion studies in obese C
G I (Before W.R) G I
Range Mean S. D Ran
1 44–52 47.6 ± 3.21 49–
70–87 77.2 ± 6.53 74–
1/FVC 45–52 48.2 ± 3.11 44–
R 54–62 58.6 ± 2.88 56–
25–75% 28–35 32.8 ± 2.95 27–
O 64–82 72.2 ± 6.50 71–
100–121 112.8 ± 8.47 110
131–146 138.2 ± 7.05 155
150–178 163.6 ± 11.28 180
64–91 75.8 ± 9.71 101
80–87 83.4 ± 2.70 70–
32–38 34.6 ± 2.19 26–
niﬁcant.
e 2 Spirometric, lung volumes and diffusion studies in obese a
G II (Before W.R) G II
Range Mean S. D Ran
1 66–75 69 ± 5.74 83–8
72–82 78 ± 4.64 90–9
1/FVC 84–95 89 ± 4.00 88–9
R 40–54 47 ± 5.57 56–6
25–75% 39–54 45.6 ± 5.41 50–5
O 95–111 103 ± 5.66 100–
82–94 86.8± 5.22 82–9
75–92 84 ± 6.60 85–9
100–125 113.4 ± 9.40 105–
60–78 71 ± 7.00 81–9
71–80 74.8 ± 3.35 66–7
32–40 36.6 ± 2.97 27–3
niﬁcant.Results
In the obese COPD group, there was an insigniﬁcant increase
of percent of predicted of FEV1, FVC, FEV1/FVC, PEFR,
FEF25–75%, DLCO and TLC after weight reduction. Percent
of predicted of FRC, ERV and RV were signiﬁcantly increased
after weight reduction. In contrast, percent of predicted of IC
was signiﬁcantly decreased (Table 1). In the asthma group,
percent of predicted of FEV1, FVC, FEV1/FVC, PEFR,
FEF25–75% and ERV were signiﬁcantly increased after weight
reduction but percent of DLCO, TLC, RV and FRC were
insigniﬁcantly increased, but, percent of predicted of IC was
insigniﬁcantly decreased (Table 2).
Discussion
Guimaraesa et al. found that FEV1 and FVC were normal in
obese persons but they were signiﬁcantly increased after weight
reduction [13]. Lazarus et al. found that the FEV1 to FVC
ratio decreases with increasing BMI in overweight and obese
individuals [14]. In morbidly obese subjects, Biring et al. found
a reduction in mid-expiratory ﬂows and the FEV1 to FVC
ratio [15]. Sahebjami and Gartside found that reduced FEV1
and FVC in obese subjects were associated with normalOPD patients before and after weight reduction (W.R).
(After W.R) t Test p Value
ge Mean S. D
55 51.2 ± 2.68 3.703 0.091
89 83.4 ± 7.30 2.002 0.195
55 50.8 ± 4.76 1.043 0.337
64 60.8 ± 3.27 1.274 0.292
40 34.8 ± 5.89 0.461 0.516
85 77.2 ± 5.07 1.841 0.212
–135 123.4 ± 11.35 2.802 0.133
–175 165.2 ± 7.92 32.429 0.001*
–199 191.8 ± 7.89 20.983 0.002*
–120 111 ± 7.97 39.285 0.001*
78 74 ± 3.54 22.313 0.001*
29 27.4 ± 1.52 36.507 0.001*
sthmatic patients before and after weight reduction (W.R).
(After W.R) t test p Value
ge Mean S. D
7 84.75 ± 1.71 5.036 0.049*
5 93 ± 2.94 3.472 0.048*
4 91.25 ± 5.12 1.968 0.203
7 62 ± 4.97 17.677 0.004*
9 54.5 ± 3.70 7.789 0.027*
112 105.25 ± 5.12 0.381 0.557
6 88± 5.83 0.106 0.754
7 91.25 ± 5.06 3.261 0.114
121 114.75 ± 7.41 0.055 0.822
0 85.25 ± 3.69 13.342 0.008*
5 70.25 ± 3.69 3.764 0.094
0 28.5 ± 1.29 25.388 0.001*
776 B.I. El-Shafey, A.E. El-DeibFEV1 to FVC ratio [16]. Li et al. found reduced FRC and dif-
fusion impairment and this, reduction in static lung volume
was correlated with the degree of obesity [17]. Obese subjects
had a reduction in the expiratory reserve volume (ERV) due
to decreased FRC by the mass loading effect of obesity. This
may be accompanied by regional gas trapping in poorly venti-
lated lung units due to small airway closure and subsequent
atelectasis [18]. Biring et al., Jenkins and Moxham concluded
that TLC was normal in both mild and morbid obesity
[18,19]. Guimaraesa et al. found that TLC was normal in obese
persons and was signiﬁcantly increased after weight reduction
[13]. In contrast, FRC and RV were less than normal levels
and after weight reduction, there was a signiﬁcant increase of
FRC but insigniﬁcant as regards RV [13]. Carbon monoxide
diffusion capacity (DLCO) increased with increasing obesity
and reversed with weight loss due to an increase in pulmonary
blood volume. Also, DLCO is directly related to the lung vol-
ume at which it is measured and any tendency toward reduced
lung volumes with obesity will decrease DLCO. A low to nor-
mal DLCO in obesity may represent a loss of pulmonary cap-
illary bed (as seen with atelectasis), especially at high BMIs
[20]. In this study, obese COPD patients showed an insigniﬁ-
cant increase of percent of predicted of FEV1, FVC,
FEV1/FVC, PEFR, FEF25–75%, DLCO after weight reduction,
but percent of predicted of FRC, ERV and RV were signiﬁ-
cantly increased after weight reduction. In contrast, percent
of predicted of IC was signiﬁcantly decreased. Ora et al.
explore the relationship between obesity and operating lung
volumes in patients with moderate to severe COPD.
Contrary to current beliefs, the combination of obesity and
COPD was not associated with diminished exercise capacity
or greater dyspnea compared with normal weight patients with
similar reduction in FEV1. They found also, relatively reduced
lung hyperinﬂation in obese patients with COPD due to
reduced operating lung volumes at rest [21]. In the general
population, obesity is an established risk factor for reduced life
expectancy, independent of smoking status [22]. Paradoxically,
epidemiological studies have shown that the patients with
advanced COPD who are overweight or mildly to- moderately
obese have a survival advantage compared with underweight
patients [23]. This ‘‘obesity paradox’’ has also been described
in other chronic diseases (chronic heart failure, rheumatoid
arthritis, and chronic renal disease) but the protective mecha-
nisms are unknown [24]. It is noteworthy that this reduced risk
of mortality was not observed in obese patients with milder
COPD [25] and that subgroups of COPD patients with more
severe obesity are at a greater risk of death due to respiratory
failure than normal weight COPD [26]. There is an exponential
relation between increasing BMI and decreasing ERV [27].
This volume reduction effect occurs across all severity stages
of airway obstruction and is seen even as BMI increases from
normal weight to the overweight range. TLC and RV are rel-
atively less affected by the increasing weight in COPD.
Importantly, as in health, the resting IC increases in response
to increasing BMI across all severity stages, reﬂecting the
greater reduction in end expiratory lung volume relative to
TLC [28]. Obesity and COPD have various inﬂuences on res-
piratory physiology, some are similar and some are opposite.
The relationship between BMI and either functional residual
capacity or expiratory reserve volume is not affected by the
presence of airﬂow obstruction [21]. However, obese COPD
patients are less hyperinﬂated compared to their leancounterparts [21]. Moreover, for a given FEV1, IC is higher
in obese subjects [29]. These changes seem beneﬁcial to
COPD subjects, counteracting some of the deleterious effects
of the disease. However, oxygen consumption is higher for a
given workload for obese subjects, leading to higher ventila-
tory demand. This increased ventilatory requirement further
stresses the respiratory system whose capacity is already
reduced by the presence of airﬂow limitation [30]. Adipose tis-
sue is the main lipid storage depot in the body and is of crucial
importance in buffering the daily inﬂux of dietary fat entering
the circulation. One characteristic of adipose tissue in obesity
is the enlargement of adipocytes which may represent impaired
adipocyte differentiation. The hypertrophic adipocytes of
obese subjects are overloaded with stored triacylglycerol and
it is likely that the buffering capacity for further lipid storage
in these adipocytes is decreased, especially in the postprandial
state. Non-adipose tissues are therefore exposed to an exces-
sive inﬂux of lipids which could lead to ectopic fat deposition
[31]. Adipose tissue is often considered to be an abundant
source of pro-inﬂammatory mediators [32]. Systemic inﬂam-
mation is considered a hallmark of COPD [33] and increased
levels of pro-inﬂammatory mediators have been reported in
the circulation of COPD patients [30]. However, not all
patients with COPD demonstrate systemic inﬂammation. In
the ECLIPSE (Evaluation of COPD Longitudinally to
Identify Predictive Surrogate Endpoints) study, only 16% of
patients with COPD had persistent systemic inﬂammation at
baseline [34]. However, it is interesting to note that the patients
with systemic inﬂammation in this study were more obese, with
a mean BMI of 29.4 Kg/m2, compared to a mean BMI of
25.6 Kg/m2 in the group without persistent systemic inﬂamma-
tion [34]. Increased levels of systemic inﬂammation had been
earlier reported in relation to excessive fat mass in COPD
patients. Speciﬁcally, tumor necrosis factor-a, interleukin
(IL)-6 and leptin levels in plasma have been shown to be signif-
icantly increased in overweight/obese COPD patients com-
pared with normal-weight patients [35] and the likelihood of
having elevated C-reactive protein in COPD patients was
found to be 3.3 times higher in obese patients compared to
normal-weight patients, after adjusting for relevant con-
founders [36]. A study by Rutten et al. also demonstrated that
abdominal fat mass is positively associated with plasma C-
reactive protein levels in patients with COPD [37].
Interestingly, it has been shown that non-obese patients with
COPD with more visceral fat mass compared to control sub-
jects were associated with increased IL-6 levels [38].
McDonald et al. concluded that, in obese COPD patients, diet-
ary energy restriction coupled with resistance strength training
results in clinically signiﬁcant improvements in BMI, exercise
tolerance and health status, while preserving skeletal muscle
mass and importantly, this intervention resulted in an
improved prognostic score [39]. In the present study, obese
asthmatic patients showed that percent of predicted of FEV1,
FVC, FEV1/FVC, PEFR, FEF25–75% and ERV were signiﬁ-
cantly increased after weight reduction but percent of DLCO
was insigniﬁcantly increased. Hakala et al. concluded that
weight loss reduces airway obstruction as well as peak expira-
tory rate variability in obese patients with asthma [40]. As
patients decreased their body mass index from 37.2 Kg/m2 to
32.1 kg/m2, diurnal PEF variation declined from 5.5% to
4.5%,day-to-day variation declined from 5.3% to 3.1%.
The mean morning PEF, FEF25–75%, FEV1, FVC, FRC and
Effect of weight reduction on obese patients 777ERV increased after weight loss [40]. Camargo et al. carried
out one of the ﬁrst longitudinal studies in adults, showing that
women who gained weight after 18 years of age ran a greater
risk of developing asthma in the next 4 years, regardless of
caloric intake or physical activity [41]. Castro-Rodrı´guez
et al. in the ﬁrst longitudinal study of a pediatric population,
showed that girls, but not boys, who became obese or over-
weight between 6 and 11 years of age ran a 7-fold greater risk
of developing asthma than those who maintained normal
nutrition and growth [42]. Stenius-Aarniala et al. and
Dhabuwala et al. concluded that when obesity precedes the
onset of asthma, it has a greater effect on progress of disease
and weight reduction either by diet or gastric bypass has been
reported to improve asthmatic symptoms [43,44]. Obesity pro-
duces decreased tidal volume and functional residual capacity,
both of which reduce the tidal stretch of smooth muscle thus,
the ability to respond to natural stress such as exercise is ham-
pered by small tidal volumes [45]. Also, Obesity increased
gastro-esophageal reﬂux due to accompanied esophageal
sphincter relaxation, resulting in esophageal acid reﬂux passing
into the trachea and airways. The direct contact of gastric acid
with the airways causes bronchoconstriction owing to the
resulting micro-aspiration or to the vagal reﬂex [46]. Leptin
plasma levels have been positively correlated with body fat,
stimulating the release of tumor necrosis factor (TNF-a) by
adipocytes and act on the sympathetic nervous system which
is crucial in controlling airway tone and diameter; important
factors in asthma [47]. TNF-a is elevated in asthma and is
related to the production of T helper-2 cytokines as IL-4
[48]. There are common genes, playing a role in both asthma
and obesity as chromosomes 5q, 6, 11q13, and 12q [45].
Adipose tissue contains the enzyme aromatase, which is
responsible for converting androgens into estrogens causing
airway hyper-reactivity and greater severity of irreversible air-
ﬂow obstruction [49]. Saraivaa et al. found that experimentally
induced obesity in mice leading to alveolar collapse, bron-
choconstriction, increased collagen ﬁber content in airways
and alveolar septa also, the high fat diet led to a further
increase in epithelial cell detachment, eosinophil and neu-
trophil inﬁltration, and elastic ﬁber fragmentation [50].
Obesity yielded larger chest wall circumferences, which
resulted in lower tidal volume, alveolar collapse, and a reduc-
tion in the diameter of airways. However, in the presence of
obesity, asthma is not simply a mechanical phenomenon. In
this line, Shore and colleagues have shown that obese mice
have increased airway hyper-responsiveness independent of
lung volume [51], possibly associated with augmentation of
the inﬂammatory process. The impact of obesity on the remod-
eling process may result from chronic repetitive injury to the
airway wall caused by inﬂammation [52]. Increased IL-4 and
IL-5 may play a role in the regulation of collagen synthesis
by stimulating transforming growth factors (TGF) and
increasing the expression of type I collagen through activation
of transcription factors [53]. Furthermore, VEGF may also
cause a marked increase in inﬂammation, followed by inﬁltra-
tion with mononuclear cells, eosinophils, and neutrophils in
lung parenchyma [54], also, Lumeng et al. and Foster et al.
concluded that obesity is accompanied with pulmonary
inﬂammation and remodeling due to lipid droplet accumula-
tion in lungs through pulmonary lipotoxicity [55,56].
Ghobashy et al. found that collagen deposition and elasticﬁber destruction could be reversed when inﬂammatory process
improved due to removal of the triggering cause, such as air
pollution in their study [57] and this might occur in this study
due to weight reduction and thus, explained the improvement
of airway obstruction. So, it was concluded that weight reduc-
tion improved airway obstruction insigniﬁcantly in obese
COPD and signiﬁcantly in asthma and increased ERV, RV
and FRC. As regards DLCO, it was increased in both
COPD, asthma after weight reduction. Some demerits are pre-
sent in this study, control and obese groups are preferred to be
included, also, study of some mediators in blood and broncho-
alveolar lavage and measurement of waist circumference and
visceral fat in addition to BMI may be helpful.
Conﬂict of interest
No conﬂict of interest.
References
[1] A.E. Dixon, F. Holguin, A. Sood, C.M. Salome, R.E. Pratley,
D.A. Beuther, J.C. Celedon, S.A. Shore, An ofﬁcial American
Thoracic Society Workshop report: obesity and asthma, Proc.
Am. Thorac. Soc. 7 (2010) 325–335.
[2] L. Maddox, D.A. Schwartz, The pathophysiology of asthma,
Annu. Rev. Med. 53 (2002) 477–498.
[3] D. Broide, New perspectives on mechanisms underlying chronic
allergic inﬂammation and asthma in 2007, J. Allergy Clin.
Immunol. 122 (2008) 475–480.
[4] Y.F. Yeh, S.L. Huang, Enhancing effect of dietary cholesterol
and inhibitory effect of pravastatin on allergic pulmonary
inﬂammation, J. Biomed. Sci. 11 (2004) 599–606.
[5] M. Decramer, B.F. De, P.A. Del, S. Marinari, Systemic effects
of COPD, Respir. Med. 99 (Suppl. B) (2005) S3–S10.
[6] F. Sava, L. Laviolette, S. Bernard, M.J. Breton, J. Bourbeau, F.
Maltais, The impact of obesity on walking and cycling
performance and response to pulmonary rehabilitation in
COPD, BMC Pulm. Med. 10 (2010) 55.
[7] C.G. Cote, B.R. Celli, BODE index: a new tool to stage and
monitor progression of chronic obstructive pulmonary disease,
Pneumonol. Alergol. Pol. 77 (2009) 305–313.
[8] A.M. Schols, J. Slangen, L. Volovics, E.F. Wouters, Weight loss
is a reversible factor in the prognosis of chronic obstructive
pulmonary disease, Am. J. Respir. Crit. Care Med. 157 (1998)
1791–1797.
[9] C.R. Swinburn, B.G. Cooper, H. Mould, et al, Adverse effect
of additional weight on exercise against gravity in patients
with chronic obstructive airways disease, Thorax 44 (1989)
716–720.
[10] A.M. Roza, H.M. Shizgal, The Harris Benedict equation
reevaluated, Am. J. Clin. Nutr. 40 (1) (1984) 168–182.
[11] R.F. Lemanske, W.W. Busse, Asthma: clinical expression and
molecular mechanisms, J. Allergy Clin. Immunol. 125 (2 Suppl.
2) (2010) S95–S102.
[12] National Institute for Health and Clinical Excellence, Clinical
Guideline 101: Chronic Obstructive Pulmonary Disease,
London, June 2010.
[13] C. Guimara˜esa, M.V. Martinsa, J. Moutinho dos Santosa,
Pulmonary function tests in obese people candidate to bariatric
surgery, Rev. Port. Pneumol. 18 (3) (2012) 115–119.
[14] R. Lazarus, D. Sparrow, S.T. Weiss, Effects of obesity and fat
distribution on ventilatory function, Chest 111 (1997) 891–898.
[15] M.S. Biring, M.I. Lewis, J.T. Liu, Z. Mohsenifar, Pulmonary
physiologic changes of morbid obesity, Am. J. Med. Sci. 318
(1999) 293–297.
778 B.I. El-Shafey, A.E. El-Deib[16] H. Sahebjami, P.S. Gartside, Pulmonary function in obese
subjects with a normal FEV1/FVC ratio, Chest 110 (1996) 1425–
1429.
[17] A.M. Li, D. Chan, E. Wong, J. Yin, E.A.S. Nelson, T.F. Fok,
The effects of obesity on pulmonary function, Arch. Dis. Child.
88 (2003) 361–363.
[18] C.S. Ray, D.Y. Sue, G. Bray, J.E. Hansen, K. Wasserman,
Effects of obesity on respiratory function, Am. Rev. Respir. Dis.
128 (1983) 501–506.
[19] S.C. Jenkins, J. Moxham, The effects of mild obesity on lung
function, Respir. Med. 85 (1991) 309–311.
[20] K. Parameswaran, D. Todd, M. Soth, Altered respiratory
physiology in obesity, Can. Respir. J 13 (4) (2006) 203–210.
[21] J. Ora, P. Laveneziana, D. Oﬁr, A. Deesomchok, K. Webb, D.
O’Donnell, Combined effects of obesity and chronic obstructive
pulmonary disease on dyspnea and exercise tolerance, Am. J.
Respir. Crit. Care Med. 180 (2009) 964–971.
[22] A. Peeters, J.J. Barendregt, F. Willekens, et al, Obesity in
adulthood and its consequences for life expectancy: a lifetable
analysis, Ann. Intern. Med. 138 (1) (2003) 24–32.
[23] E. Chailleux, J.P. Laaban, D. Veale, Prognostic value of
nutritional depletion in patients with COPD treated by
longterm oxygen therapy: data from the ANTADIR
observatory, Chest 123 (5) (2003) 1460–1466.
[24] K. Kalantar-Zadeh, T.B. Horwich, A. Oreopoulos, et al, Risk
factor paradox in wasting diseases, Curr. Opin. Clin. Nutr.
Metab. Care 10 (4) (2007) 433–442.
[25] C. Landbo, E. Prescott, P. Lange, J. Vestbo, T.P. Almdal,
Prognostic value of nutritional status in chronic obstructive
pulmonary disease, Am. J. Respir. Crit. Care Med. 160 (6)
(1999) 1856–1861.
[26] J.G. Jordan Jr., J.R. Mann, Obesity and mortality in persons
with obstructive lung disease using data from the NHANES III,
South. Med. J. 103 (4) (2010) 323–330.
[27] D.E.O’. Donnell, A. Deesomchok, Y.M. Lam, et al, Effects of
BMI on static lung volumes in patients with airway obstruction,
Chest 140 (2011) 461–468.
[28] J. Ora, P. Laveneziana, K. Wadell, M. Preston, K.A. Webb,
D.E. Donnell, Effect of obesity on respiratory mechanics during
rest and exercise in COPD, J. Appl. Physiol. 111 (1) (2011) 10–
19.
[29] R.L. Jones, M.M. Nzekwu, The effects of body mass index on
lung volumes, Chest 130 (2006) 827–833.
[30] V. Pepin, D. Saey, L. Laviolette, F. Maltais, Exercise capacity in
chronic obstructive pulmonary disease: mechanisms of
limitation, COPD 4 (2007) 195–204.
[31] K.N. Frayn, Adipose tissue and the insulin resistance syndrome,
Proc. Nutr. Soc. 60 (2001) 375–380.
[32] A. Sood, Obesity, adipokines, and lung disease, J. Appl. Physiol.
108 (3) (2010) 744–753 (1985).
[33] W.Q. Gan, S.F. Man, A. Senthilselvan, D.D. Sin, Association
between chronic obstructive pulmonary disease and systemic
inﬂammation: a systematic review and a meta-analysis, Thorax
59 (7) (2004) 574–580.
[34] A. Agusti, L.D. Edwards, S.I. Rennard, et al, Persistent
systemic inﬂammation is associated with poor clinical
outcomes in COPD: a novel phenotype, PLoS ONE 7 (5)
(2012) e37483.
[35] M. Poulain, M. Doucet, V. Drapeau, et al, Metabolic and
inﬂammatory proﬁle in obese patients with chronic obstructive
pulmonary disease, Chron. Respir. Dis. 5 (1) (2008) 35–41.
[36] M.K. Breyer, M.A. Spruit, A.P. Celis, et al, Highly elevated C-
reactive protein levels in obese patients with COPD: a fat
chance?, Clin Nutr. 28 (6) (2009) 642–647.
[37] E.P. Rutten, M.K. Breyer, M.A. Spruit, et al, Abdominal fat
mass contributes to the systemic inﬂammation in chronic
obstructive pulmonary disease, Clin. Nutr. 29 (6) (2010) 756–
760.[38] B. van den Borst, H.R. Gosker, G. Wesseling, et al, Low-grade
adipose tissue inﬂammation in patients with mild-to-moderate
chronic obstructive pulmonary disease, Am. J. Clin. Nutr. 94 (6)
(2011) 1504–1512.
[39] V. McDonald, P. Gibson, H. Scott, P. Baines, M. Hensley, J.
Pretto, L. Wood, Obesity in COPD, how should it be managed?
– The effect of weight loss and resistance training in obese
COPD patients, ERJ 44 (Suppl. 58) (2014) P3035.
[40] K. Hakala, B. Stenius-Aarniala, A. Sovija, Effects of weight loss
on peak ﬂow variability, airways obstruction, and lung volumes
in obese patients with asthma, Chest 118 (2000) 1315–1321.
[41] C.A. Camargo Jr, S.T. Weiss, S. Zhang, W.C. Willett, F.E.
Speizer, Prospective study of body mass index, weight change,
and risk of adult-onset asthma in women, Arch. Intern. Med.
159 (1999) 2582–2588.
[42] J.A.Castro-Rodrı´guez, C.J.Holberg,W.J.Morgan,A.L.Wright,
F.D. Martı´nez, Increased incidence of asthma-like symptoms in
girls who become overweight or obese during the school years,
Am. J. Respir. Crit. Care Med. 163 (2001) 1344–1349.
[43] B. Stenius-Aarniala, T. Poussa, J. Kvarnstrom, E.L. Gronlund,
M. Ylikahri, P. Mustajoki, Immediate and long term effects of
weight reduction in obese people with asthma: randomised
controlled study, BMJ 320 (2000) 827–832.
[44] A. Dhabuwala, R.J. Cannan, R.S. Stubbs, Improvement in co-
morbidities following weight loss from gastric bypass surgery,
Obes. Surg. 10 (2000) 428–435.
[45] K.G. Tantisira, S.T. Weiss, Complex interactions in complex
traits: obesity and asthma, Thorax 56 (Suppl. 2) (2001) 64–73.
[46] S.J. Sontag, Gastroesophageal reﬂux disease and asthma, J.
Clin. Gastroenterol. 30 (3 Suppl.) (2000) 9–30.
[47] D.D. Sin, S.F. Man, Impaired lung function and serum leptin in
men and women with normal body weight: a population based
study, Thorax 58 (2003) 695–698.
[48] M. Visser, L.M. Bouter, G.M. McQuillan, M.H. Wener, T.B.
Harris, Lowgrade systemic inﬂammation in overweight children,
Pediatrics 107 (2001) e13.
[49] R.Varraso,V. Siroux, J.Maccario, I. Pin,F.Kauffmann,Asthma
severity is associated with bodymass index and early menarche in
women, Am. J. Respir. Crit. Care Med. 171 (2005) 334–339.
[50] S.A. Saraivaa, A.L. Silva, D.G. Xistoa, S.C. Abreua, Impact of
obesity on airway and lung parenchyma remodeling in
experimental chronic allergic asthma, Respir. Physiol.
Neurobiol. 177 (2011) 141–148.
[51] S.A. Shore, Obesity and asthma: lessons from animal models, J.
Appl. Physiol. 102 (2007) 516–528.
[52] M.A. Antunes, S.C. Abreu, A.L. Silva, E.R. Parra-Cuentas,
A.M. Ab’Saber, V.L. Capelozzi, T.P. Ferreira, M.A. Martins,
P.M. Silva, P.R. Rocco, Sex-speciﬁc lung remodeling and
inﬂammation changes in experimental allergic asthma, J. Appl.
Physiol. 109 (2010) 855–863.
[53] F.Q. Wen, X.D. Liu, Y. Terasaki, Q.H. Fang, T. Kobayashi, S.
Abe, S.I. Rennard, Interferon-gamma reduces interleukin-4- and
interleukin-13-augmented transforming growth factor-beta2
production in human bronchial epithelial cells by targeting
Smads, Chest 123 (2003) 372S–373S.
[54] R.J. Homer, J.A. Elias, Airway remodeling in asthma:
therapeutic implications of mechanisms, Physiology (Bethesda)
20 (2005) 28–35.
[55] C.N. Lumeng, A.R. Saltiel, Inﬂammatory links between obesity
and metabolic disease, J. Clin. Invest. 121 (2011) 2111–2117.
[56] D.J. Foster, P. Ravikumar, D.J. Bellotto, R.H. Unger, C.C.
Hsia, Fatty diabetic lung. Altered alveolar structure and
surfactant protein expression, Am. J. Physiol. Lung Cell. Mol.
Physiol. 298 (2010) L392–L403.
[57] H.A. Ghobashy, U.A. Elmeleegy, H.S. Seleem, Histological,
histochemical, immunohistochemical and morphometric study
of adult male albino rat’s lung following exposure to air
pollution Egypt, J. Histol. 33 (1) (2010) 140–155.
